Time Boost Capital

Time Boost Capital is a venture fund dedicated to investing in early-stage companies that develop genomics solutions. It provides match funding and leverages accelerator programs to select and validate startups focused on advancing human health through innovative genomic technologies and applications. The fund is designed to cultivate promising ventures in the rapidly evolving genomics landscape.

The fund, Time Boost Capital I LP, was launched in 2020, advised by Time Partners Limited. Its inception stemmed from a collaborative insight among founding investors Illumina, LifeArc, and Genome Research Limited, recognizing the need to accelerate the growth of genomics entrepreneurs and companies within the UK. Kevin Smith is a Managing Partner at Time Partners, while Sally Ann Forsyth chairs the fund's Investment Committee.

Time Boost Capital primarily serves nascent companies specializing in genomics, aiming to commercialize scientific breakthroughs. The fund’s overarching vision is to foster a robust ecosystem where groundbreaking genomics innovations can flourish, ultimately delivering new diagnostic tools, therapies, and preventative measures to improve global health outcomes.